1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019 Date – Oct 01, 2019 Product – Zirabev (biosimilar, bevacizumab) The biosimilar was launched in […]readmore
Tags : Novartis
Shots: The EC’s approval is based on P-III EXPAND study assessing Mayzent vs PBO in patients with SPMS with active disease defined as patients with relapses in the two years […]readmore
Shots: Novartis to receive up front, milestones on the initiation of dosing in different phases of clinical development and approval of the IOV-3001 in the US, EU, and Japan along […]readmore
The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list […]readmore
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
Shots: Akcea retains exclusive rights to develop and commercialize AKCEA-APOCIII-LRx following Novartis’ decision for not exercising the option In 2017, Novartis signed an option agreement with Akcea for two antisense […]readmore
Shots: The P-III LUSTER-1 & 2 studies involve assessing of Fevipiprant (150/ 450mg) vs PBO in 894 & 877 patients aged ≥12yrs. in a ratio (1:1:1) with moderate-severe asthma, receiving […]readmore
1. Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune […]readmore
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA […]readmore
Shots: Forendo to receive up front, equity investment, development, regulatory and commercial milestones with royalties on sales. Novartis to fund the research activities and will be responsible for development, manufacturing […]readmore